RAP-219 – Talk Bio

Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219

5 days ago talkbio0Tagged clinical seizure, Epilepsy, focal onset seizures, meeting, Phase 2a Trial, Phase 3 trials, RAP-219, Rapport Therapeutics, seizure drug, United States Food and Drug Administration

Rapport Therapeutics; RAP-219; Phase 2a trial; seizure drug; epilepsy; focal onset seizures; clinical seizure reduction; FDA meeting; Phase 3 trials

Expert Flags Potential ‘Honeymoon Effect’ as Rapport Heads Towards Phase III Epilepsy Trials

1 month ago talkbio0Tagged Biological Markers, drug-resistant focal seizures, Epilepsy, Honeymoon Effect, KOL Bulletin, mid-stage, Phase 3 Clinical Trials, RAP-219, Rapport Therapeutics, Seizures

KOL Bulletin; honeymoon effect; Rapport Therapeutics; RAP-219; Phase III trials; epilepsy; drug-resistant focal seizures; seizure reduction; mid-stage data; biomarker

Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

3 months ago talkbio0Tagged anti-seizure medication, Clinical Development, drug-resistant epilepsy, Epilepsy, focal onset seizures, RAP-219, Rapport Therapeutics, Seizures

Rapport Therapeutics; RAP-219; epilepsy; seizure reduction; Phase 2a clinical trial; focal onset seizures; Phase 3 trials; anti-seizure medication; drug-resistant epilepsy; clinical development

Rapport Therapeutics Faces Regulatory Hurdles in Pain Treatment Trials

1 year ago talkbio0Tagged Clinical Development, RAP-219, Rapport Therapeutics, regulatory, treatment pain

Rapport Therapeutics, pain treatment trials, regulatory challenges, RAP-219, clinical development